CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
Latest:

Galcanezumab

Galcanezumab

The CGRP monoclonal antibody, Emgality (galcanezumab), was approved for the prevention of migraine in adults in September 2018 and, in June 2019, became the first and only anti-CGRP therapy to be approved for the prevention of episodic cluster headache in adults. These approvals were supported by data including the results of the EVOLVE 1 and 2 trials in episodic migraine, the REGAIN trial in chronic migraine and a Phase 3 study in cluster headache. The CONQUER trial investigated the efficacy of galcanezumab in patients with migraine who had failed on 2-4 previous preventive therapies.


Download slideset »


« back to Slides